Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Postive Metastatic Breast Cancer (MBC)

Document Type

Presentation

Publication Date

12-6-2022

Keywords

oregon; portland; chiles

Clinical Institute

Cancer

Clinical Institute

Women & Children

Specialty

Oncology

Comments

Geyer CE, Tang G, Rastogi P, Valero V, Chia SK, Cobain EF, Obeid E, Page DB, Poklepovic AS, Irvin WJ, Brufsky AM, Wapnir IL, Suga JM, Mamounas E, Wolmark N. SABCS Annual Meeting; December 6-10; San Antonio, TX. 2022: OT2-16-05.

This document is currently not available here.


Share

COinS